A Phase III Randomized Double-Blind Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

Recruiting
99 years or below
All
Phase 3
1 Location

Brief description of study

The purpose of the study is to compare letermovir to valganciclovir in preventing CMV disease in patients who have received a kidney transplant and are considered to be at high-risk for CMV disease after their transplant. The main study intervention is taking letermovir (or placebo for letermovir) plus valanciclovir (or placebo for valganciclovir) for 28 weeks after kidney transplant, instead of receiving the standard of 6 months valganciclovir post-transplant.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 13 Feb 2019. Study ID: 829228

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.